ANSTO Publications Online: An investigation into the potential of SarAr for use in Cu-64 radioimmunotherapy.

Please use this identifier to cite or link to this item: http://apo.ansto.gov.au/dspace/handle/10238/3029

Title:	An investigation into the potential of SarAr for use in Cu-64 radioimmunotherapy.
Authors:	Di Bartolo, N Smith, SV Hetherington, E Sargeson, A
Keywords:	Radioimmunotherapy Iodine 123 Copper 64 Mice Dosimetry Drugs
Issue Date:	13-Oct-2009
Publisher:	CSIRO Publishing
Citation:	Di Bartolo, N., Smith, S. V., Hetherington, E., & Sargeson, A. (2009). An investigation into the potential of SarAr for use in Cu-64 radioimmunotherapy. Australian Journal of Chemistry, 62(10), 1261-1270.
Abstract:	The B72.3 monoclonal antibody was radiolabelled with 123I, and with 111In and 64Cu, using DTPA and SarAr, respectively. Their biodistribution in tumour-bearing nude mice was used to calculate the dosimetry of their respective therapeutic analogue, using 131I, 90Y, 67Cu, and 64Cu. Two dosimetry models were used: one using the classical approach and a second model that takes into consideration the chemical stability of the radiolabelling methods employed and the biological clearance of each radioimmunoconjugate. Results clearly show that the 64Cu-SarAr-B72.3 could be used as a therapeutic agent and, theoretically, be at least as effective as any of the other therapeutic radionuclides currently studied, such as 131I, 90Y, and 67Cu. © 2009, CSIRO Publishing
URI:	http://dx.doi.org/10.1071/CH09369 http://apo.ansto.gov.au/dspace/handle/10238/3029
ISSN:	0004-9425
Appears in Collections:	Journal Articles

Files in This Item:

There are no files associated with this item.